Mark K Bennett
Affiliations: | 1993-1999 | Molecular and Cell Biology | University of California, Berkeley, Berkeley, CA, United States |
| 2010- | Calithera Biosciences, Inc. |
Website:
https://www.calithera.com/persons/mark-k-bennett-ph-d/Google:
"Mark Knowles Bennett" OR "Mark K Bennett"Bio:
Bennett, Mark Knowles Brain Type II Calcium and Calmodulin-Dependent Protein Kinase: Purification, Characterization and Molecular Cloning. Dissertation (Ph.D.), California Institute of Technology (1986).
Mean distance: (not calculated yet)
Cross-listing: Cell Biology Tree
Parents
Sign in to add mentor| Mary B. Kennedy | grad student | 1986 | Caltech | |
| (Brain Type II Calcium and Calmodulin-Dependent Protein Kinase: Purification, Characterization and Molecular Cloning) | ||||
Children
Sign in to add trainee| Charles Kwok Fai Chan | research assistant | 1996-1999 | UC Berkeley (Stem Cell Tree) |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Emberley ED, Bennett M, Chen J, et al. (2018) Abstract 3509: The glutaminase inhibitor CB-839 synergizes with CDK4/6 and PARP inhibitors in pre-clinical tumor models Cancer Research. 78: 3509-3509 |
| Steggerda SM, Bennett MK, Chen J, et al. (2017) Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment. Journal For Immunotherapy of Cancer. 5: 101 |
| Papadopoulos KP, Tsai FY, Bauer TM, et al. (2017) CX-1158-101: A first-in-human phase 1 study of CB-1158, a small molecule inhibitor of arginase, as monotherapy and in combination with an anti-PD-1 checkpoint inhibitor in patients (pts) with solid tumors. Journal of Clinical Oncology. 35: 3005-3005 |
| DeMichele A, Harding J, Telli M, et al. (2017) Abstract P6-11-05: Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), in combination with paclitaxel (Pac) in patients (its) with triple negative breast cancer (TNBC) Cancer Research. 77 |
| Meric-Bernstam F, Tannir NM, Mier JW, et al. (2016) Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC). Journal of Clinical Oncology. 34: 4568-4568 |
| DeMichele A, Harding JJ, Telli ML, et al. (2016) Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS) in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC). Journal of Clinical Oncology. 34: 1011-1011 |
| Steggerda SM, Bennett M, Chen J, et al. (2016) Abstract B045: Arginase inhibitor CB-1158 elicits immune-mediated antitumor responses as a single agent and in combination with other immunotherapies Cancer Immunology Research. 4 |
| Works M, Bennett M, Chen J, et al. (2016) Abstract 552: Immuno-oncology agent CB-1158 is a potent and selective arginase inhibitor and causes an immune-mediated anti-tumor response Cancer Research. 76: 552-552 |
| Emberley E, Bennett M, Chen J, et al. (2016) CB-839, a selective glutaminase inhibitor, has anti-tumor activity in renal cell carcinoma and synergizes with everolimus and receptor tyrosine kinase inhibitors European Journal of Cancer. 69 |
| Steggerda S, Bennett M, Chen J, et al. (2016) Arginase inhibitor CB-1158 elicits immune-mediated anti-tumor responses as a single agent and enhances the efficacy of other immunotherapies European Journal of Cancer. 69 |